Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion

Hogyoung Kim; Amrita Datta; Sudha Talwar; Sarmad N. Saleem; Debasis Mondal; Asim B. Abdel-Mageed

doi:10.18632/oncotarget.11355

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion

Hogyoung Kim, Amrita Datta, Sudha Talwar, Sarmad N. Saleem, Debasis Mondal and Asim B. Abdel-Mageed _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:62820-62833. https://doi.org/10.18632/oncotarget.11355

Metrics: PDF 1946 views | HTML 3107 views | ?

Abstract

Hogyoung Kim1, Amrita Datta1, Sudha Talwar1, Sarmad N. Saleem1, Debasis Mondal2 and Asim B. Abdel-Mageed1,2,3

1Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana, 70112, USA

2Department of Pharmacology, Tulane University School of Medicine, New Orleans, Louisiana, 70112, USA

3Tulane Cancer Center, Tulane University School of Medicine, New Orleans, Louisiana, 70112, USA

Correspondence to:

Asim B. Abdel-Mageed, email: [email protected]

Keywords: estrogen, ERβ2, TMPRSS2:ETV5, IGF-1R, prostate cancer

Received: September 02, 2015 Accepted: July 26, 2016 Published: August 17, 2016

ABSTRACT

Estrogen receptor beta (ERβ) splice variants are implicated in prostate cancer (PC) progression; however their underlying mechanisms remain elusive. We report that non-canonical activation of estradiol (E₂)-ERβ2 signaling axis primes growth, colony-forming ability and migration of the androgen receptor (AR)-null castration-resistant PC (CRPC) cells under androgen-deprived conditions (ADC). The non-classical E₂-ERβ2 mediates phosphorylation and activation of Src-IGF-1R complex, which in turn triggers p65-dependent transcriptional upregulation of the androgen-regulated serine protease TMPRSS2:ETV5a/TMPRSS2:ETV5b gene fusions under ADC. siRNA silencing of TMPRSS2 and/or ETV5 suggests that TMPRSS2:ETV5 fusions facilitates the E₂-ERβ induced growth and migration effects via NF-κB-dependent induction of cyclin D1 and MMP2 and MMP9 in PC-3 cells. Collectively, our results unravel the functional significance of oncogenic TMPRSS2:ETV5 fusions in mediating growth and migration of E₂-ERβ2 signaling axis in CRPC cells. E₂-ERβ2 signaling axis may have significant therapeutic and prognostic implications in patients with CRPC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11355

Publication Alerts

Research Papers:

Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion

Abstract